- Home
- ESQ vs XERS Comparison
ESQ vs XERS Comparison
Compare ESQ & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESQ
- XERS
- Stock Information
- Founded
- ESQ 2006
- XERS 2005
- Country
- ESQ United States
- XERS United States
- Employees
- ESQ N/A
- XERS N/A
- Industry
- ESQ Commercial Banks
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- ESQ Finance
- XERS Health Care
- Exchange
- ESQ Nasdaq
- XERS Nasdaq
- Market Cap
- ESQ 525.7M
- XERS 444.0M
- IPO Year
- ESQ 2017
- XERS 2018
- Fundamental
- Price
- ESQ $76.50
- XERS $3.09
- Analyst Decision
- ESQ Buy
- XERS Buy
- Analyst Count
- ESQ 4
- XERS 3
- Target Price
- ESQ $68.00
- XERS $4.87
- AVG Volume (30 Days)
- ESQ 24.9K
- XERS 1.8M
- Earning Date
- ESQ 10-24-2024
- XERS 11-08-2024
- Dividend Yield
- ESQ 0.78%
- XERS N/A
- EPS Growth
- ESQ 2.35
- XERS N/A
- EPS
- ESQ 4.95
- XERS N/A
- Revenue
- ESQ $116,205,000.00
- XERS $187,361,000.00
- Revenue This Year
- ESQ N/A
- XERS $20.35
- Revenue Next Year
- ESQ $11.52
- XERS $16.14
- P/E Ratio
- ESQ $15.45
- XERS N/A
- Revenue Growth
- ESQ 10.32
- XERS 22.72
- 52 Week Low
- ESQ $44.45
- XERS $1.69
- 52 Week High
- ESQ $76.91
- XERS $3.64
- Technical
- Relative Strength Index (RSI)
- ESQ 68.77
- XERS 49.74
- Support Level
- ESQ $69.86
- XERS $2.82
- Resistance Level
- ESQ $76.91
- XERS $3.12
- Average True Range (ATR)
- ESQ 2.52
- XERS 0.18
- MACD
- ESQ 0.10
- XERS -0.03
- Stochastic Oscillator
- ESQ 97.03
- XERS 32.93
About ESQ Esquire Financial Holdings Inc.
Esquire Financial Holdings Inc is a full-service commercial bank dedicated to serving the financial needs of the legal industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The Bank offers tailored products and solutions to the legal community and their clients as well as dynamic and flexible payment processing solutions to small business owners. Banking products offered for businesses and consumers include checking, savings, money market, and time deposits; a wide range of commercial and consumer loans, as well as customary banking services. The Bank operates a payment processing platform through third-party Independent Sales Organizations.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.